# Study of FMT Combined With Nivolumab in Gastric Cancer

> **NCT05001360** · NA · WITHDRAWN · sponsor: **Fujian Cancer Hospital**

## Conditions studied

- Gastric Adenocarcinoma
- Esophagogastric Junction Adenocarcinoma
- Esophagus Adenocarcinoma

## Interventions

- **DRUG:** XBI-302 + Nivolumab

## Key facts

- **NCT ID:** NCT05001360
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10
- **Primary completion:** 2023-10
- **Final completion:** 2023-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** We could not get the IRB approval.
- **Last updated:** 2021-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05001360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05001360, "Study of FMT Combined With Nivolumab in Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05001360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*